TheraVet significantly expands its BIOCERA-VET® product line through major distribution and research agreements

News and research before you hear about it on CNBC and others. Claim your 1-week free trial for Street Insider Premium here.

  • Addition of two new complementary lines of veterinary bone substitutes to the BIOCERA-VET® portfolio
  • Access to personalized 3D bio-printed bone parts for sophisticated veterinary bone grafting surgeries
  • Research collaboration on new generation proprietary bone substitutes for veterinary applications

GOSSELIES, Belgium – (BUSINESS WIRE) – Regulatory news:

Theravet (ISIN: BE0974387194 – ticker: ALVET), a pioneer in the management of bone and joint diseases in companion animals, today announced a partnership considerably expanding TheraVet’s portfolio of bone substitutes with (i) 2 new lines of exclusive and complementary bone grafts, (ii) 3D bio-printed bone endoprostheses for tailor-made bone grafts and (iii) product development new generation exclusives.

Thanks to an exclusive worldwide distribution agreement with INNOTERE, one of the undisputed leaders in bone biomaterials (Radebeul, Germany), TheraVet is expanding its range of bone substitutes to veterinary orthopedic surgeons with 2 new exclusive ranges of biomaterials: first with first-in – ready-to-use injectable calcium phosphate bone cement pastes with extended working time particularly well suited for complex minimally invasive bone grafting procedures and secondly with biosynthetic granules of ultra-fine size.

In addition, TheraVet adds 3D bio-printed calcium phosphate bone substitutes to its portfolio. This technology allows the manufacture of complex implants specifically designed according to the needs of the patient and the surgeon while ensuring optimal physicochemical, biocompatibility and resorbability properties. One envisioned application is the provision of personalized biocompatible stents in the management of canine osteosarcoma.

Finally, thanks to the R&D agreement, new generation bone substitutes will be jointly developed. These R&D programs focus on the design, development and industrialization of innovative bone substitutes (i) with enhanced shear-thinning properties in order to facilitate their injectability, increase their workability and overall improve their ergonomics, (ii) with improved osteogenic / osteoforming properties in order to fix and improve bone consolidation and healing and (iii) associated with active molecules, thus acting as a local drug delivery device. In this joint collaboration agreement, each party will file its own patents, allowing TheraVet to strengthen its intellectual property position with new proprietary bone substitutes.

Enrico Bastianelli, CEO of TheraVet, concludes: “This partnership is a great opportunity to expand TheraVet’s portfolio of bone substitutes. Indeed, INNOTERE has an impressive track record in the development of innovative bone biomaterials with high added value for human applications which will certainly be profitable for the veterinary market ”.

About TheraVet SA

TheraVet is a veterinary biotechnology company specializing in bone and joint treatments for animals. The Company develops targeted, safe and effective treatments to improve the quality of life of animals suffering from osteoarticular diseases. For pet owners, the health of their animals is a major concern and TheraVet’s mission is to meet the need for innovative and curative treatments. TheraVet works in close collaboration with international opinion leaders in order to provide a more effective response to the ever increasing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris and Brussels, its head office is in Gosselies, Belgium, and it has a subsidiary in the United States.

For more information visit the TheraVet website

Or follow us on LinkedIn / Facebook / Twitter


Sabrina ena


[email protected]

Julie winand

Chief Executive Officer

[email protected]

Phone: +32 (0) 71 18 32 49


Investor Relations and Financial Communication

Louis Tilquin / Olivier Bricaud

[email protected]

Phone: +33 (0) 1 44 71 94 94

Press relations

Arthur Rouillé / Ambre Delval

[email protected]

Phone: +33 (0) 1 44 71 00 15

Source: TheraVet

Source link

Comments are closed.